CTi Biopharma Corp Alpha and Beta Analysis
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CTi Biopharma Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in CTi Biopharma over a specified time horizon. Remember, high CTi Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CTi Biopharma's market risk premium analysis include:
Beta 0.35 | Alpha 1.47 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
CTi |
CTi Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CTi Biopharma market risk premium is the additional return an investor will receive from holding CTi Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CTi Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CTi Biopharma's performance over market.| α | 1.47 | β | 0.35 |
CTi Biopharma Fundamentals Vs Peers
Comparing CTi Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CTi Biopharma's direct or indirect competition across all of the common fundamentals between CTi Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as CTi Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CTi Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CTi Biopharma to competition |
| Fundamentals | CTi Biopharma | Peer Average |
| Return On Equity | -10.19 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Profit Margin | (0.91) % | (1.27) % |
| Operating Margin | (0.74) % | (5.51) % |
| Current Valuation | 1.26 B | 16.62 B |
| Shares Outstanding | 131.88 M | 571.82 M |
| Shares Owned By Insiders | 5.49 % | 10.09 % |
CTi Biopharma Opportunities
CTi Biopharma Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Is CTI BioPharma Corp a Bad Choice in Biotechnology Thursday - InvestorsObserver | 03/30/2023 |
2 | CTI BioPharma Shares Soar Premarket on Takeover by Swedish Orphan CTIC | 05/10/2023 |
3 | CTi Biopharma earnings beat, revenue topped estimates | 05/12/2023 |
4 | CTI BioPharma Q1 Earnings Snapshot | 05/16/2023 |
5 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates FOCS, HMPT, CTIC | 05/18/2023 |
6 | Top 5 Health Care Stocks That Should Keep You Up At Night By ... - Investing.com UK | 05/23/2023 |
7 | Gyon Technologies Capital Management LP Raises Position in CTI BioPharma Corp. | 06/09/2023 |
8 | Disposition pursuant to a tender of shares in a change of control transaction by Reed Tuckson of CTi Biopharma | 06/26/2023 |
About CTi Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CTi or other delisted stocks. Alpha measures the amount that position in CTi Biopharma Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
CTi Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of CTi Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CTi Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CTi Biopharma. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.
| 14th of August 2023 Upcoming Quarterly Report | View | |
| 6th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with CTi Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |